RANKL/OPG与人多发性骨髓瘤骨病的关系
摘要
多发性骨髓瘤(MM)是以骨髓微环境中浆细胞恶性增殖为特征的血液肿瘤。细胞核因子κB受体活化因子配基(RANKL) /护骨素(OPG)与MM发病关系密切。在MM中,存在RANKL表达上调、OPG表达下调;这种RANKL/OPG比率异常与MM骨病及骨病范围、MM的肿瘤负荷、分期和预后均有关。
出处
《国外医学（生理病理科学与临床分册）》
2005年第2期151-152,共2页
Foreign Medical Sciences(Pathophysiology and Clinical Medicine)
参考文献13
-
1Croucher P1, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma[J].Blood,2001,98 ( 13 ) :3534-3540. 被引量：1
-
2Sezer O, Heider U, Zavrski l, et al. Rank ligand and osteoprotegerin in myeloma bone disease[J]. Blood,2003,101 (6) :2094-2098. 被引量：1
-
3Giuliani N, Batallle R, Mancinl C, et al. Myeloma cell induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment [J]. Blood, 2001,98 ( 13 ) : 3527-3533. 被引量：1
-
4Roux S, Meignin V, Quillard J, et al. Rank ( receptor activator of nuclear factor-κB ) and rankl expression in multiple myeloma[J]. Br J Haematol,2002,117 ( 1 ) : 86-92. 被引量：1
-
5Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand ( rankl ) in T lymphocytes: a potential role in multiple myeloma bone disease [J].Blood,2002,100 ( 13 ) :4615-4621. 被引量：1
-
6Farrugia AN,Atkins GJ,Bikto L, et al. Receptor activator of nuclear factor-κB expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo [J].Catwer Res,2003 ,63(10):5438-5445. 被引量：1
-
7Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor-κB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma [J].Clin Cancer Res,2003,9 ( 12 ) :1436-1440. 被引量：1
-
8Sezer O, Heider U, jakob C, et al. lmmunocytochemistry reveals RANKL expression of myeloma cells [J]. Blood, 2002,99 (12) : 4646-4647. 被引量：1
-
9Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor-κB ligand - osteoprotegefin ratio ptedicts survival in multiple myeloma : proposal for a novel prognostic index[J]. Blood,2003,102 ( 3 ) : 1064-1069. 被引量：1
-
10Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and sufival via cell-cell contact:a vicious cycle between bone destruction and myeloma expansion [J]. Blood, 2004, 104 ( 8 ) :2484 -2491. 被引量：1
-
1谢林森.护骨素用于前列腺癌骨转移的研究[J].中国煤炭工业医学杂志,2009,12(7):1024-1024.
-
2单浩,夏守慧,周芸,杨伟平.应用硼替佐米为主方案对多发性骨髓瘤患者β2-MG、CRP及OPG的影响[J].中国生化药物杂志,2016,36(5):63-65. 被引量：7
-
3付蓉,邵宗鸿.多发性骨髓瘤骨病病理机制研究进展[J].中华血液学杂志,2004,25(2):125-127. 被引量：16
-
4段文义,牛俊杰,崔晓萍,李俊芳,彭英杰.伊班膦酸钠和帕米膦酸二钠分别联合化疗治疗多发性骨髓瘤骨病的疗效分析[J].基层医学论坛,2015,19(27):3783-3784. 被引量：2
-
5翟勇平.老年多发性骨髓瘤骨病防治[J].实用老年医学,2013,27(9):716-719.
-
6陈明治,蒋国军,谈永飞,王洪敏,唐巍峰,谈志刚,龚泽刚,史国振.护骨素和可溶性核因子кB受体活化因子配体在非小细胞肺癌诊断和鉴别诊断中的意义[J].中国肿瘤临床与康复,2015,22(3):261-263. 被引量：1
-
7胡永珍,李达.益肾活血饮配合亚砷酸治疗多发性骨髓瘤骨病的观察[J].辽宁中医杂志,2009,36(8):1331-1333. 被引量：7
-
8卢瑞青,张晓红.护骨素及相关因子与多发性骨髓瘤骨病的关系[J].国外医学（输血及血液学分册）,2005,28(1):57-60. 被引量：1
-
9骈晓琴,高大.miR-214及miR-135b在多发性骨髓瘤骨病中的研究进展[J].肿瘤研究与临床,2017,29(1):70-72. 被引量：3
-
10张建华,傅晋翔,张晓慧,孙谕.破骨细胞在多发性骨髓瘤发病中的作用[J].中华血液学杂志,2007,28(5):323-326. 被引量：9
